Core Insights - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight management in overweight or obese adults, enhancing competition in a market projected to be worth billions in the coming years [1] Group 1: Product Approval and Market Impact - The approval of Xianweiying, also known as ecnoglutide, is seen as a significant advancement in the field of weight management [2] - The market for weight management drugs is competitive, with sales of Novo Nordisk's Wegovy and Innovent's Xinermei reported at 260 million yuan ($38 million) and 416 million yuan ($61 million) respectively in 2025 [2] Group 2: Licensing and Strategic Moves - In February, Pfizer licensed the mainland China commercialization rights for Xianweiying from Sciwind Biosciences, marking a strategic step in Pfizer's global strategy in the metabolic field in China [3] - Ecnoglutide is also approved in China for the treatment of Type II diabetes, indicating its dual application in the healthcare market [3]